Oral Versus Vaginal Combined Hormonal Contraceptives' Effect on Coagulation and Inflammatory Biomarkers Among Young Adult Women
Oral Versus Vaginal Combined Hormonal Contraceptives' Effect on Coagulation and Inflammatory Biomarkers Among Young Adult Women
复制标题
DOI：
10.1177/1076029612440036
复制
发表时间：
2012-09-01
影响因子：
2.9
通讯作者：
Datta, Yvonne H.
中科院分区：
文献类型：
--
作者：
Divani, Afshin A.;Luo, Xianghua;Datta, Yvonne H.
为了比较联合口服避孕药（COC）和联合阴道避孕药（CVC）方法对炎症和促凝的影响，我们招募了3组女性参与者：对照组参与者，COC用户和CVC用户。我们测量了不同的血液生物标志物。COC和CVC的使用者的C反应蛋白（P < .0001）和因子VII（P < .0001）水平较高。然而，CD 40配体仅在COC使用者中更高（P < .0001），而不是CVC使用者。尽管凝血酶/抗凝血酶III的水平对于COC和CVC使用者而言并不高于对照组，但CVC使用者与COC使用者相比具有更高的水平（P = 0.0327）。与对照组相比，我们在CVC使用者中观察到更高水平的von Willebrand因子，但COC使用者没有。需要更大样本量的纵向研究，以更好地评估CVC使用引起的炎症和促凝反应。
In order to compare the effect of combined oral contraceptive (COC) and combined vaginal contraceptive (CVC) methods on the inflammation and procoagulation, we recruited female participants in 3 groups: control participants, COC users, and CVC users. We measured different blood biomarkers. The users of both COC and CVC had higher levels of C-reactive protein (P < .0001) and factor VII (P < .0001). However, CD40 ligand was only higher for COC users (P < .0001) and not the CVC users. Even though the levels of thrombin/antithrombin III were not higher for COC and CVC users, as compared to the controls, CVC users had higher levels as compared to COC users (P = .0327). As compared to the control group, we observed higher levels von Willebrand factor among CVC users but not the COC users. Longitudinal studies with larger sample size are needed to better assess the inflammatory and procoagulation response due to CVC use.